# HEALTH: Antibiotic Resistance Acceleration & Economic Implications Antibiotic-resistant infections kill approximately 1.27 million people annually and cause 10 million additional deaths indirectly through treatment failures, with projections estimating 10 million deaths yearly by 2050 if resistance patterns continue—surpassing cancer mortality. The World Health Organization identifies antimicrobial resistance (AMR) as a top-10 global health threat, yet antibiotics developed in the 1980s remain the backbone of modern medicine; only two new antibiotic classes entered clinical practice since 2000 compared to 15 new classes between 1935-1987. Economic modeling shows AMR could cost the global economy $100+ trillion in lost GDP by 2050, primarily through reduced surgical capacity (30% of procedures require antibiotic prophylaxis) and extended hospitalizations that strain healthcare systems already fragmented across developed and developing nations. This matters because antibiotic stewardship failures today directly erode the foundation of modern surgery, chemotherapy, organ transplantation, and trauma care—returning medicine to pre-1940s mortality rates unless development incentives and prescribing practices shift fundamentally.